AFP-L3 was found to be insensitive in the diagnosis of HCC in patients with low-level AFP and, hence, using a better fraction method, AFP-L3% with a specificity of 85.1% was demonstrated to have better utility in patients with AFP-negative liver cancer. The gene discussed is AFP; the disease is hepatocellular carcinoma.